Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells
The DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.
Abstract
Iron overload secondary to beta-thalassemia and other iron-loading anemias is the most serious obstacle to be overcome in the treatment of these diseases, since there is no physiological mechanism for excretion of the excess iron acquired by chronic blood transfusion. Due to the inconvenience and cost of the current iron chelation therapy, the search for an orally available iron chelator is ongoing. Pyridoxal isonicotinoyl hydrazone (PIH) and many of its analogs are effective at mobilizing iron in vivo and in vitro at doses that are not toxic. PIH analogs were approximately equally effective at binding 59Fe within K562 cells; their efficacy depended upon the kinetics of release of the iron-chelator complex from the cell, which was correlated inversely with the lipophilicity of the chelators. Addition of BSA, which has a well-characterized affinity for lipophilic species, to the extracellular medium enhanced iron-chelator efflux, such that all analogs caused 59Fe release from the cells as quickly as it was chelated; this suggests that BSA acts as an extracellular sink for the iron-chelator complexes, many of which are highly lipophilic. The toxicity of the free chelators varied over two orders of magnitude, and was correlated with the amount of intracellular 59Fe-chelator complexes, implicating the complexes in the mechanism of toxicity of the chelators. Understanding the structural features that determine the efficacy and toxicity of iron chelators in biological systems is of value in the selection of PIH analogs for in vivo examination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, pyridoxal isonicotinyl hydrazone (PIH) [1672,1715-1720] is a promising molecule (also proposed in anti-cancer therapy), although it is hydrolysed both in vivo and in vitro [1721].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1717]
Citations
Cites
Oxygen toxicity, oxygen radicals, transition metals and disease
Halliwell, B., & Gutteridge, J. M. C. (1984) · Biochemical Journal · doi:10.1042/bj2190001 · Cited by 5,330
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
Richardson, D. R., & Ponka, P. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/s0304-4157(96)00014-7 · Cited by 704
Self-citationRichardson, D., Tran, E., & Ponka, P. (1995) · Blood · doi:10.1182/blood.v86.11.4295.bloodjournal86114295 · Cited by 345
Self-citationRichardson, D. R., & Milnes, K. (1997) · Blood · doi:10.1182/blood.v89.8.3025 · Cited by 205
Poňka, P., Borová, J., Neuwirt, J., Fuchs, O., & Nečas, E. (1979) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(79)90100-4 · Cited by 183
Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron‐Loaded Subjects
Summers, M. R., Jacobs, A., Tudway, D., Perera, P., & Ricketts, C. (1979) · British Journal of Haematology · doi:10.1111/j.1365-2141.1979.tb01167.x · Cited by 179
Darnell, G., & Richardson, D. R. (1999) · Blood · doi:10.1182/blood.v94.2.781 · Cited by 167
Evidence that transferrin supports cell proliferation by supplying iron for DNA synthesis
Laskey, J. D., Webb, I. J., Schulman, H. M., & Ponka, P. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90123-1 · Cited by 145
Self-citationBaker, E., Richardson, D., Gross, S., & Ponka, P. (1992) · Hepatology · doi:10.1002/hep.1840150323 · Cited by 130
Self-citation
Cited by
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Synthesis, characterization and biological activity of Ni, Cu and Zn complexes of isatin hydrazones
Rodríguez-Argüelles, M. C., Ferrari, M. B., Bisceglie, F., Pelizzi, C., Pelosi, G., Pinelli, S., & Sassi, M. (2003) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2003.10.006 · Cited by 218
Subarkhan, M. K. M., Saranya, S. V., & Ramesh, R. (2017) · Inorganic Chemistry Frontiers · doi:10.1039/c7qi00761b · Cited by 176
El-Tabl, A. S., El-Saied, F. A., Plass, W., & Al‐Hakimi, A. N. (2007) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2007.11.011 · Cited by 95
Metadata
- Authors
- Buss, J. L., Arduini, E., Shephard, K. C., & Ponka, P.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Ponka, Prem
- ORCID
- Ponka, Prem
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2003-02
- Volume
- 65
- Issue
- 3
- Pages
- 349-360
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2032136371
- Cited by
- 41
- References
- 36
- Citations by year
- 2024: 2 · 2022: 2 · 2021: 2 · 2020: 1 · 2017: 2 · 2016: 1 · 2015: 1 · 2013: 1 · 2012: 3
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Biochemical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- pyridoxal isonicotinoyl hydrazone, iron chelators, lipophilicity, iron efflux, beta-thalassemia, iron overload, K562 cells, BSA, oral iron chelation, structure-activity relationship
- MeSH terms
- Antineoplastic Agents, Biological Transport, Cell Division, Humans, Iron, Iron Chelating Agents, Isoniazid, Pyridoxal, K562 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells. https://app.cochat.ai/papers/10.1016/s0006-2952(02)01551-4
- The paper
- Buss, J. L., Arduini, E., Shephard, K. C., & Ponka, P. (2003). Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells. Biochemical Pharmacology. https://doi.org/10.1016/s0006-2952(02)01551-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.